{"schema_version":"secwatch.filing_event.v1","accession":"0001823239-24-000105","form_type":"8-K","ticker":"MRVI","cik":"0001823239","company_name":"MARAVAI LIFESCIENCES HOLDINGS, INC.","filed_at":"2024-11-07T23:59:59+00:00","discovered_at":"2026-05-14T18:03:09.844334+00:00","generated_at":"2026-05-30T03:47:10.792709+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"Maravai reports Q3 loss of $176M on $154.2M goodwill impairment; acquires Officinae Bio DNA/RNA business","bullets":["Q3 revenue $65.2M (down 2.5% YoY); net loss $(176.0)M includes $154.2M goodwill impairment.","Adjusted EBITDA $12.7M vs $11.9M in Q3 2023.","FY2024 revenue guidance lowered to $255-265M (from prior outlook).","Agreed to acquire Officinae Bio's DNA/RNA business (AI-driven platform); close expected early 2025.","Nucleic Acid Production revenue $49.9M (down 2.5% YoY); Biologics Safety Testing $15.3M (down 2.5%)."],"urls":{"canonical":"https://secwatch.observer/filing/0001823239-24-000105","json":"https://secwatch.observer/filing/0001823239-24-000105.json","markdown":"https://secwatch.observer/filing/0001823239-24-000105.md","text":"https://secwatch.observer/filing/0001823239-24-000105.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1823239/000182323924000105/0001823239-24-000105-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1823239/000182323924000105/mrvi-20241107.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-30T03:47:10.792709+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}